0001104659-22-042917.txt : 20220405 0001104659-22-042917.hdr.sgml : 20220405 20220405194145 ACCESSION NUMBER: 0001104659-22-042917 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220401 FILED AS OF DATE: 20220405 DATE AS OF CHANGE: 20220405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Buchholz Richard CENTRAL INDEX KEY: 0001737133 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38468 FILM NUMBER: 22809003 MAIL ADDRESS: STREET 1: C/O INSPIRE MEDICAL SYSTEMS, INC. STREET 2: 9700 63RD AVENUE NORTH, SUITE 200 CITY: MAPLE GROVE STATE: MN ZIP: 55369 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inspire Medical Systems, Inc. CENTRAL INDEX KEY: 0001609550 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 261377674 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 WAYZATA BLVD STREET 2: SUITE 1600 CITY: GOLDEN VALLEY STATE: MN ZIP: 55416 BUSINESS PHONE: 763-957-5037 MAIL ADDRESS: STREET 1: 5500 WAYZATA BLVD STREET 2: SUITE 1600 CITY: GOLDEN VALLEY STATE: MN ZIP: 55416 4 1 tm2211772-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-04-01 0 0001609550 Inspire Medical Systems, Inc. INSP 0001737133 Buchholz Richard C/O INSPIRE MEDICAL SYSTEMS, INC. 5500 WAYZATA BLVD., SUITE 1600 GOLDEN VALLEY MN 55416 0 1 0 0 Chief Financial Officer Common Stock 2022-02-17 5 G 0 E 250 0 D 62426 D Common Stock 2022-02-17 5 G 0 E 125 0 A 1125 I By Daughter Common Stock 2022-02-17 5 G 0 E 125 0 A 1125 I By Son Common Stock 2022-02-18 5 G 0 E 250 0 D 62176 D Common Stock 2022-02-18 5 G 0 E 125 0 A 1125 I By Son Common Stock 2022-02-18 5 G 0 E 125 0 A 1125 I By Son Common Stock 2022-04-01 4 S 0 5500 259.46 D 56676 D Common Stock 2022-04-01 4 S 0 5362 258.50 D 51314 D Common Stock 2022-04-01 4 S 0 4037 257.90 D 47277 D Common Stock 2022-04-01 4 S 0 101 255.99 D 47176 D Includes 52 shares acquired under the Inspire Medical Systems, Inc. (the "Company") 2018 Employee Stock Purchase Plan on December 31, 2021. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.10 to $259.675. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.04 to $259.01. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.04 to $258.03. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Bryan Phillips as Attorney-in-Fact for Richard Buchholz 2022-04-05